ClinicalTrials.gg
Not yet recruitingNCT07047963ENDIUpdated Jul 2, 2025

Neuropsychological Evaluation in Intellectual Disability (ENDI)

An observational study in Down Syndrome (Trisomy 21), Neuropsychology and Cognitive Aging, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 1 site in France. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
40
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Down Syndrome with a site in France — 12 open to participants now, 12 under way, none of them phase 3. Down Syndrome · France.

Planned enrollment
19th of 23
40 · median 100
Started
2025
with 4 others
Observational
23 of 40
6 open now
Primary completion
2026-08
later than 2 of 11 live
Registered
35th of 40
by date
Lead sponsor
1 of 40
Central Hospital, Nancy, France

Among the 40 studies in Down Syndrome with a site in France, this one is the 19th largest by planned enrollment of the 23 observational ones that give a count, is one of 5 that started in 2025, is one of 23 observational ones, reaches primary completion later than 2 of the 11 other live ones, and was the 35th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

12 of the 40 studies in Down Syndrome with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Down Syndrome with a site in France, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate the acceptability ofpatients with trisomy 21 (T21) to perform the full battery of ENDI neurospychological tests and each of the subsets.

In this study, three types of population will be recruted : normotypic volunteers, patients with Intellectual Disability and patients T21carriers.

This study is separated into 2 phases :

  • A the preliminary phase : this phase will be used to evaluate subtest design, ergonomics and understanding of instructions, and to identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company. In this phase, normotypical volunteers and patients with intellectual disabilities will be recruted to perform ENDI test battery.
  • A main phase : this phase will enable to answer to the main objective. in this phase, patients with Trisomy 21 aged between 25 and 65 will be recruted to perform ENDI test battery.
Read the detailed description

Trisomy 21 is a genetic disease resulting from a chromosomal anomaly, due to a triplication, bringing the total number of chromosomes to 47. In addition to physical characteristics, adults with Trisomy 21 (T21) generally have an intelligence quotient (IQ) score suggesting mild (IQ: 50-69) to moderate (IQ: 35-49) intellectual disability (ID), and adaptive functional impairments corresponding to this level of ID severity. Progress in medical and social care has led to a significant increase in life expectancy for trisomy 21 patients. De Graaf, Buckley \& Skotko (2021) estimate the number of trisomy 21 patients in France at around 35,000, 42% of whom are aged 40 or over. According to Asselin (2005), by 2030, the number of people with intellectual disabilities (ID) aged over 60 should have doubled.

This raises questions about the ageing of this population, all the more so as it is likely to occur earlier, due to reduced neuronal reserve. For example, signs of aging appear 10 years earlier in people with ID, at around age 55. Moreover, this aging process is said to be accelerated Normal cognitive aging in trisomy 21 patients is poorly characterized in the literature; similarly, there is no consensus regarding prodromal signs of Alzheimer's Disease (AD) in T21. However, the presence of the supernumerary chromosome containing the APP (Amyloid Precursor Protein) gene increases the risk of developing AD: 20% of trisomy 21 patients aged 45 and over develop a major neurocognitive disorder (MNCD), and over 50% by the age of 55. T21 is now considered a genetic form of AD, similar to an autosomal dominant form. Identifying AD in this population is therefore a real challenge, especially as AD is identified as the cause of 70% of deaths in trisomy 21 patients.

In cognitive terms, the precursor signs of AD are impairment of memory and temporo-spatial orientation, followed by impairment of praxis, language and visuo-spatial skills. Other authors suggest an early decline in executive functions. More recently, Startin et al. (2019) show that memory and attention tests are more sensitive in detecting prodromal forms. Establishing a diagnosis of neurodegenerative disease in trisomy 21 patients is important for at least 3 reasons. People with intellectual disabilities are often treated with neuroleptics, whose use is not recommended in AD. It also contributes to the adaptation of medical and social care, as ageing disabled people with AD will experience less frequent difficulties, including behavioural changes. According to the Edinburgh Principles, it is important to "ensure that appropriate diagnostic, assessment and intervention resources and services are available to meet the individual needs and promote the healthy ageing of people with intellectual disabilities and cognitive impairment". Finally, at a time when promising pharmacological treatments for AD are emerging for neurotypical subjects, it seems crucial that trisomy 21 patients, who are more at risk of AD, should be diagnosed as early as possible so that they can ultimately benefit from these new therapies. Neuropsychological assessment plays a crucial role in the diagnostic process, as brain imaging and lumbar puncture for AD biomarkers in cerebrospinal fluid are not always feasible.

However, a number of problems remain:

  • Neuropsychological assessment is conditioned by the severity of the intellectual disability and the level of literacy/numeracy.
  • Few adapted tests are available in French. Tests used in the general population are not transposable, and those based on child assessment batteries are infantilizing.
  • Few tests incorporate the evolution of digital technologies, which make it possible to offer more playful interfaces with better temporal control.
  • Few tests allow for longitudinal follow-up (no parallel versions, no longitudinal standards), whereas current recommendations call for systematic annual follow-up from the age of 30. In this context, it is essential to develop new cognitive tools integrating digital technologies and innovative approaches, which are indispensable for accurate diagnosis and monitoring of cognitive disorders in trisomy 21 patients. It was with this in mind that the ENDI (Evaluation Neuropsychologique dans la Déficience Intellectuelle) battery was designed. This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in trisomy 21 patients performance over time, the neuropsychologist can detect early signs of AD. A pre-test of the ENDI battery is planned to evaluate subtest design, ergonomics and comprehension of instructions, and to identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company.
03

Conditions studied

  • Down Syndrome (Trisomy 21)
  • Neuropsychology
  • Cognitive Aging
  • Alzheimer Disease
  • Alzheimer Disease, Early Onset

Keywords

  • Down Syndrome (Trisomy 21)
  • ENDI
  • Trisomy 21
  • neuropsychology
  • ENDI tests battery
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Normotypical volunteers, patients with intellectual disability, and Trisomie 21 patients (T21) will be recruited by psychologists during a consultation in the Geriatrics Department of the University Hospital of Nancy, either through the Memory Resource and Research Center outpatient clinic or the day hospital. Volunteers and patients are generally referred by their general practitioner or another hospital department.

Eligibility criteria

Inclusion Criteria:

Preliminary phase:

  1. The inclusion criteria for the group of people with intellectual disabilities are as follows:

    • Participant who has received full information on the organization of the research and has not objected to his or her participation and to the use of his or her data.
    • Legal guardian of the participant, if applicable, who has received full information on the organization of the research and has not objected to participation and use of his/her data.
    • Age at inclusion: ≥ 25 and ≤ 65 years
    • Notion of intellectual disability in medical records
    • Access to the oral language of the participant with an intellectual disability: the subject's speech must be comprehensible to the evaluator and the subject must be able to understand simple statements. It is not possible to use an oral comprehension test (e.g. Token test by Renzi \& Vignolo, 1962), as the norms achieved in healthy subjects would exclude almost all patients with intellectual disabilities, who have more limited language skills.
    • Enrolled in or benefiting from a social security scheme.
  2. The inclusion criteria for the normotypic group are as follows:

    • Participant having received full information on the organization of the research and not having objected to his or her participation and to the use of his or her data.
    • Age at inclusion: ≥ 25 and ≤ 65 years
    • Affiliation with a social security scheme or beneficiary of such a scheme

Main phase:

Inclusion criteria are as follows:

  • Participant with T21 who has received full information on the organization of the research and has not objected to participation and use of his/her data
  • Legal guardian of the participant with T21, where applicable, who has received full information on the organization of the research and has not objected to his or her participation and the use of his or her data.
  • Person with trisomy 21
  • Age at inclusion: ≥ 25 and ≤ 65 years
  • Access to the oral language of the participant with T21: the subject's speech must be comprehensible to the evaluator and the subject must be able to understand simple statements. It is not possible to use an oral comprehension test (e.g. Token test by Renzi \& Vignolo, 1962), as the norms achieved in healthy subjects would exclude almost all patients with intellectual disabilities, who have more limited language skills.
  • Membership of a social security scheme or beneficiary of such a scheme

Exclusion Criteria for both phases of the study are as follows:

  • Disabling motor and/or sensory impairments preventing completion of the tests
  • Insufficient command of the French language to complete the tests
  • Severe general medical condition or alcoholism (habitual consumption of 3 drinks/day or history of alcohol withdrawal)
  • History of stroke, severe head trauma, or cancer
  • Change in long-term medication within 8 weeks prior to evaluation
  • Refusal to participate by the subject and/or legal representative
  • Individuals referred to in Articles L.1121-5 to L.1121-7 of the French Public Health Code:

    • Pregnant women, women in labor, or breastfeeding mothers
    • Individuals deprived of liberty by judicial or administrative decision
    • Individuals undergoing psychiatric treatment under Article L.3213-1 of the French Public Health Code
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Trisomy 21 patients

    Trisomy 21 patients recruted on Main Phase will perform the ENDI tests in order to assess the acceptability of the subtests (individually) and the full neuropsychological battery

    Diagnostic Test: ENDI (Neuropsychological Evaluation in Intellectual Disability)

  • Patients with Intellectual Disabilities

    Patients with Intellectual Disabilities recruted on Preliminary Phase will be will carry out the ENDI tests in order to evaluate subtest design, ergonomics, understanding of instructions and identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company.

    Diagnostic Test: ENDI (Neuropsychological Evaluation in Intellectual Disability)

  • Normotypical volunteers

    Normotypical volunteers recruted on Preliminary Phase will be will carry out the ENDI tests in order to evaluate subtest design, ergonomics, understanding of instructions and identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company.

    Diagnostic Test: ENDI (Neuropsychological Evaluation in Intellectual Disability)

Interventions

  • Diagnostic testENDI (Neuropsychological Evaluation in Intellectual Disability)

    This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in Trisomy 21 patients performance over time, the neuropsychologist can detect early signs of Alzheimer's disease.

    Also known as: ENDI

06

What researchers measure

Primary outcomes

  1. Acceptability of individual subtests and the complete test battery

    Acceptability will be estimated by The average completion time for the complete ENDI battery

    Time frame: Through the study (completion of the full test battery), an average of 45 min

  2. Acceptability of individual subtests and the complete test battery

    Acceptability will be estimated by the Average completion time for each subtest of the ENDI battery

    Time frame: Through the study (completion of the full test battery), an average of 45 min

  3. Acceptability of individual subtests and the complete test battery

    Acceptability will be estimated by the Percentage of complete completion of each ENDI subtest

    Time frame: Through the study (completion of the full test battery), an average of 45 min

  4. Acceptability of individual subtests and the complete test battery

    Acceptability will be estimated by the Percentage of subjects having completed all ENDI battery subtests

    Time frame: Through the study (completion of the full test battery), an average of 45 min

Secondary outcomes

  1. The convergent validity of ENDI tests

    Correlation coefficient between ENDI scores and scores on DSQIID-F questionnaire. Scoring scale for the DSQIID-F questionnaire is from 0 to 53

    Time frame: Through the study, an average of 16 months

  2. The convergent validity of ENDI tests

    Correlation coefficient between ENDI scores and scores on BPSD-DS questionnaire . The Scoring scale for BPSD-DS questionnaire is : for each dimension, frequency is rated from 0 to 4 and severity from 0 to 3 .

    Time frame: Through the study, an average of 16 months

  3. The convergent validity of ENDI tests

    Correlation coefficient between ENDI scores and score on ISDC questionnaire. Scoring scales for ISDC questionnaire is for each dimension, frequency is scored from 0 to 4, severity from 0 to 3 and impact from 0 to 5

    Time frame: Through the study, an average of 16 months

  4. The convergent validity of ENDI tests

    Correlation coefficient between ENDI scores and scores of CAMCOG II questionnaire. The Scoring scale for CAMCOG II questionnaire is from 0 to 106, the lower the score, the greater the impairment.

    Time frame: Through the study, an average of 16 months

07

Study locations

1 site
08

References and documents

Publications

  • Hithersay R, Startin CM, Hamburg S, Mok KY, Hardy J, Fisher EMC, Tybulewicz VLJ, Nizetic D, Strydom A. Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years. JAMA Neurol. 2019 Feb 1;76(2):152-160. doi: 10.1001/jamaneurol.2018.3616. PubMed 30452522 ↗
  • Coquelet A, Besozzi A, Roussel M, Lemetayer F. Evaluation neuropsychologique des adultes porteurs d'une trisomie 21 en Consultation memoire : quels outils ? Une revue de la litterature. Geriatr Psychol Neuropsychiatr Vieil. 2022 Mar 1;20(1):79-95. doi: 10.1684/pnv.2022.1025. French. PubMed 35652846 ↗
  • Coppus AW, Fekkes D, Verhoeven WM, Tuinier S, Egger JI, van Duijn CM. Plasma amino acids and neopterin in healthy persons with Down's syndrome. J Neural Transm (Vienna). 2007;114(8):1041-5. doi: 10.1007/s00702-007-0656-1. Epub 2007 Mar 31. PubMed 17401539 ↗
  • Carmeli E, Imam B, Bachar A, Merrick J. Inflammation and oxidative stress as biomarkers of premature aging in persons with intellectual disability. Res Dev Disabil. 2012 Mar-Apr;33(2):369-75. doi: 10.1016/j.ridd.2011.10.002. Epub 2011 Nov 25. PubMed 22119683 ↗
  • Burt DB, Aylward EH. Test battery for the diagnosis of dementia in individuals with intellectual disability. Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability. J Intellect Disabil Res. 2000 Apr;44 ( Pt 2):175-80. doi: 10.1046/j.1365-2788.2000.00264.x. PubMed 10898382 ↗
  • Devenny DA, Zimmerli EJ, Kittler P, Krinsky-McHale SJ. Cued recall in early-stage dementia in adults with Down's syndrome. J Intellect Disabil Res. 2002 Sep;46(Pt 6):472-83. doi: 10.1046/j.1365-2788.2002.00417.x. PubMed 12354318 ↗
  • Startin CM, Hamburg S, Hithersay R, Al-Janabi T, Mok KY, Hardy J; LonDownS Consortium; Strydom A. Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimers Dement. 2019 Feb;15(2):245-257. doi: 10.1016/j.jalz.2018.08.009. Epub 2018 Nov 28. PubMed 30503169 ↗
  • Zis P, Strydom A. Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. Free Radic Biol Med. 2018 Jan;114:3-9. doi: 10.1016/j.freeradbiomed.2017.08.024. Epub 2017 Sep 1. PubMed 28870521 ↗
  • McCarron M, McCallion P, Reilly E, Dunne P, Carroll R, Mulryan N. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res. 2017 Sep;61(9):843-852. doi: 10.1111/jir.12390. Epub 2017 Jun 29. PubMed 28664561 ↗
  • Lott IT, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev. 2001;7(3):172-8. doi: 10.1002/mrdd.1025. PubMed 11553933 ↗
  • Lautarescu BA, Holland AJ, Zaman SH. The Early Presentation of Dementia in People with Down Syndrome: a Systematic Review of Longitudinal Studies. Neuropsychol Rev. 2017 Mar;27(1):31-45. doi: 10.1007/s11065-017-9341-9. Epub 2017 Mar 13. PubMed 28289920 ↗
  • Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm AC, Iqbal K, Krams M, Lemere C, Lott I, Mobley W, Ness S, Nixon R, Potter H, Reeves R, Sabbagh M, Silverman W, Tycko B, Whitten M, Wisniewski T. Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement. 2015 Jun;11(6):700-9. doi: 10.1016/j.jalz.2014.10.007. Epub 2014 Dec 12. PubMed 25510383 ↗
  • Godefroy O, Martinaud O, Verny M, Mosca C, Lenoir H, Bretault E, Roussel M. The dysexecutive syndrome of Alzheimer's disease: the GREFEX study. J Alzheimers Dis. 2014;42(4):1203-8. doi: 10.3233/JAD-140585. PubMed 25024318 ↗
  • Fortea J, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L, Barroeta I, Fernandez S, Altuna M, Pegueroles J, Montal V, Valldeneu S, Gimenez S, Gonzalez-Ortiz S, Munoz L, Estelles T, Illan-Gala I, Belbin O, Camacho V, Wilson LR, Annus T, Osorio RS, Videla S, Lehmann S, Holland AJ, Alcolea D, Clarimon J, Zaman SH, Blesa R, Lleo A. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020 Jun 27;395(10242):1988-1997. doi: 10.1016/S0140-6736(20)30689-9. PubMed 32593336 ↗
  • Rebillat AS, Hiance-Delahaye A, Falquero S, Radice G, Sacco S. The French translation of the dementia screening questionnaire for individuals with intellectual disabilities is a sensitive tool for screening for dementia in people with Down Syndrome. Res Dev Disabil. 2021 Nov;118:104068. doi: 10.1016/j.ridd.2021.104068. Epub 2021 Aug 28. PubMed 34467872 ↗
  • Dubois B, Touchon J, Portet F, Ousset PJ, Vellas B, Michel B. ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. Presse Med. 2002 Nov 9;31(36):1696-9. French. PubMed 12467149 ↗
  • Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988 Jun;38(6):900-3. doi: 10.1212/wnl.38.6.900. PubMed 3368071 ↗
  • Krikorian R, Bartok J, Gay N. Tower of London procedure: a standard method and developmental data. J Clin Exp Neuropsychol. 1994 Dec;16(6):840-50. doi: 10.1080/01688639408402697. PubMed 7890819 ↗
  • DE RENZI E, VIGNOLO LA. The token test: A sensitive test to detect receptive disturbances in aphasics. Brain. 1962 Dec;85:665-78. doi: 10.1093/brain/85.4.665. No abstract available. PubMed 14026018 ↗
  • Rubenstein E, Hartley S, Bishop L. Epidemiology of Dementia and Alzheimer Disease in Individuals With Down Syndrome. JAMA Neurol. 2020 Feb 1;77(2):262-264. doi: 10.1001/jamaneurol.2019.3666. PubMed 31657825 ↗
  • Ball SL, Holland AJ, Treppner P, Watson PC, Huppert FA. Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer's disease in adults with Down syndrome and mild to moderate learning disabilities. Br J Clin Psychol. 2008 Mar;47(Pt 1):1-29. doi: 10.1348/014466507X230967. PubMed 17681112 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Aug 2026, 13 months later.

Of 40 non-industry observational studies under Down Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 13 months is below that.

Counting every sponsor, half of 55 studies reached it within 34 months; a quarter within 19 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Jul 2, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Aug 31, 2026
CompletionEst.
Nov 1, 2026
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07047963
Responsible party
COQUELET Amelie (Principal Investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
Jul 2, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Aug 31, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Jul 2, 2025

Study contacts

Amélie COQUELET, Psychologist
Contact
a.coquelet@chru-nancy.fr
+33 3 83 15 79 64

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion